Oral Antidiabetic Agents - Luzimar Teixeira

410 Krentz & Bailey
References
23. Krentz AJ, Ferner RE, Bailey CJ. Comparative tolerability
profiles of oral antidiabetic agents. Drug Saf 1994; 11: 223-41
1. UK Prospective Diabetes Study Group. Intensive blood-glucose
control with sulphonylureas or insulin compared with convensevere
refractory sulfonylurea-induced hypoglycemia with oc-
24. Krentz AJ, Boyle PJ, Justice K, et al. Successful treatment of
tional treatment and risk of complications in patients with type
2 diabetes (UKPDS 33). Lancet 1998; 352: 837-53
treotide. Diabetes Care 1993; 16: 184-6
2. European Diabetes Policy Group. A desktop guide to type 2
25. Wilson SH, Kennedy FP, Garratt KN. Optimisation of the
diabetes mellitus. Diabetic Med 1999; 16: 716-30
management of patients with coronary heart disease and type 2
diabetes mellitus. Drugs Aging 2001; 18: 325-33
3. Tuomilheto J. Controlling glucose and blood pressure in type 2
diabetes. BMJ 2000; 321: 394-6
26. Schernthaner G, Grimaldi A, Di Mario U, et al. GUIDE study:
double-blind comparison of once-daily gliclazide MR and
4. Krentz AJ, Bailey CJ. Type 2 diabetes in practice. London:
glimepiride in type 2 diabetic patients. Eur J Clin Invest 2004;
Royal Society of Medicine Press, 2001
34: 535-42
5. Adler AI. Cardiovascular risk reduction in diabetes: underemphasized
and overdue: messages from major trials. Clin
27. Landgraf R. Meglitinide analogues in the treatment of type 2
Med 2001; 1: 472-7
diabetes mellitus. Drugs Aging 2000; 17 (5): 411-25
6. Beckman JA, Creager MA, Libby P. Diabetes and atherosclero-
28. Dornhorst A. Insulotropic meglitinide analogues. Lancet 2001;
sis: epidemiology, pathophysiology and management. JAMA
358: 1709-15
2002; 287: 2570-81
29. Davies M. Nateglinide: better post-prandial glucose control.
7. Gray A, Clarke P, Farmer A, et al. Implementing intensive
Prescriber 2002; 13: 17-27
control of blood glucose concentration and blood pressure in 30. Qiao Q, Tuomilehto J, Borch-Johnsen K. Post-challenge hypertype
2 diabetes in England: cost analysis. United Kingdom glycaemia is associated with premature death and macrovascu-
Prospective Diabetes Study (UKPDS) Group. BMJ 2002; 325: lar complications. Diabetologia 2002; 46 Suppl. 1: M17-21
860-3
31. Lebovitz HE. α-Glucosidase inhibitors as agents in the treat-
8. Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention ment of diabetes. Diabetes Revs 1998; 6: 132-45
and cardiovascular disease in patients with type 2 diabetes. N 32. Chiasson JL, Josse RG, Gomis R, et al. Acarbose for the
Engl J Med 2003; 348: 383-93
prevention of diabetes mellitus: the STOP-NIDDM random-
9. Turner RC, Cull CA, Frighi V, et al. Glycemic control with diet, ised trial. STOP-NIDDM Trial Research Group. Lancet 2002;
sulfonylurea, metformin, or insulin in patients with type 2 359: 2072-7
diabetes mellitus: progressive requirements for multiple theratrial
33. Holman RR, Cull CA, Turner RC. A randomised double-blind
pies. JAMA 1999; 281: 2005-12
of acarbose in type 2 diabetes shows improved glycemic
10. Evans AJ, Krentz AJ. Benefits and risks of transfer from oral control over 3 years (UK Prospective Diabetes Study 44).
antidiabetic agents to insulin in type 2 diabetes. In: Krentz AJ, Diabetes Care 1999; 22: 960-4
editor. Drug treatment of type 2 diabetes. Auckland: Adis 34. Chiasson J-L, Josse RG, Gomis R, et al. Acarbose treatment and
Books, 2000: 85-101
the risk of cardiovascular disease and hypertension in patients
11. Seltzer HS. A summary of criticisms of the findings and conclu- with impaired glucose tolerance: the STOP-NIDDM trial. The
sions of the University Group Diabetes Program. Diabetes STOP-NIDDM Trial Research Group. JAMA 2003; 290:
1972; 21: 976-9
486-94
12. Krentz AJ. Sulfonylureas in the prevention of vascular compliprevention
35. Scheen A. Is there a role for alpha-glucosidase inhibitors in the
cations: from UKPDS to the ADVANCE study. Proceedings
of type 2 diabetes mellitus? Drugs 2003; 63 (10):
of the VIIIth European symposium on metabolism. Amster- 933-51
dam: Elsevier Science International Congress Series 1253; 36. Reaven GM. Role of insulin resistance in human disease. Diabe-
2003: 261-77
tes 1988; 37: 1595-607
13. Evans AJ, Krentz AJ. Glimepiride: a new sulphonylurea. Prescriber
37. Krentz AJ. Insulin resistance. Oxford: Blackwell Science, 2002
1999; 10: 51-8
38. Ginsberg HN. Insulin resistance and cardiovascular disease. J
14. Ashcroft FM, Gribble FM. ATP-sensitive K+ channels and Clin Invest 2000; 106: 453-8
insulin secretion: their role in health and disease. Diabetologia 39. Campbell IW. Antidiabetic drugs past and future: will improv-
1999; 42: 903-19 ing insulin resistance benefit cardiovascular risk in type 2
15. Gribble FM, Reimann F. Pharmacological modulation of KATP diabetes mellitus? Drugs 2000; 60 (5): 1017-28
channels. Biochem Soc Trans 2002; 30: 333-9 40. Bailey CJ, Turner RC. Metformin. N Engl J Med 1996; 334:
16. Rorsman P, Renstrom E. Insulin granule dynamics in pancreatic 574-9
beta cells. Diabetologica 2003; 46: 1029-45
41. Kirpichnikov D, McFarlane SI, Sowers JR. Metformin: an up-
17. Groop LC. Sulfonylureas in NIDDM. Diabetes Care 1992; 15: date. Ann Intern Med 2002; 137: 25-33
1737-54 42. Cusi K, DeFronzo RA. Metformin: a review of its metabolic
18. Rendell M. The role of sulfonylureas in the management of type effects. Diabetes Rev 1998; 6: 89-131
2 diabetes. Drugs 2004; 64 (12): 1339-58 43. Zhou G, Myers R, Li Y, et al. Role of AMP-activated protein
19. Bailey CJ, Day C. Antidiabetic drugs. Br J Cardiol 2003; 10: kinase in the mechanism of action of metformin. J Clin Invest
128-36 2001; 108: 1167-74
20. Yki-Järvinen H. Combination therapies with insulin in type 2 44. Winder WW, Hardie DG. AMP-activated protein kinase, a
diabetes. Diabetes Care 2001; 24: 758-67
metabolic master switch: possible roles in type 2 diabetes. Am
21. DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus.
J Physiol 1999; 277: E1-E10
Ann Intern Med 1999; 131: 281-303
45. Lord JM, Flight IHK, Norman RJ. Metformin in polycystic
22. Lebovitz HE. Insulin secretagogues: old and new. Diabetes ovary syndrome: systematic review and meta-analysis. BMJ
Revs 1999; 7: 139-53 2003; 327: 951-5
© 2005 Adis Data Information BV. All rights reserved. Drugs 2005; 65 (3)